There’s no argument that the future of medicine is in biotech, not old pharma. Two companies in particular stands out the most and they are AMGN and DNA. These two companies have great pipeline, management, and earnings (not just potential). Between these two companies, I favor AMGN because of lower PE and zero debt. I believe these two companies are great investment and will continue to accumulate shares on pull backs.

This entry was posted on Wednesday, September 7th, 2005 at 11:15 am and is filed under Stock. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.